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In the recent NICE appraisals for rheumatoid arthritis the six companies involved each independently 
conducted systematic reviews, economic modelling and network meta-analyses [1]. Each will have 
incurred substantial agency fees and internal time to manage the projects. Given the models were 
also based on a very similar structure, each needed to solve very similar problems (independently) 
from the perspective of disease progression. This is a typical situation, with examples ranging from 
psoriasis, chronic obstructive pulmonary disease, and multiple myeloma with multiple companies 
creating almost identical models. In contrast, only a few examples exist of standardised models 
available to use by all (under varying frameworks [2,3]) - diabetes is the only example that readily 
springs to mind [4]. 
Whilst this may be the norm for our industry [5], we contend this does not represent a valuable use 
of scarce resources. Were companies to collaborate on modelling and evidence generation activities 
at the least at the disease level, there would be large benefits. These vary from improved modelling 
(reducing uncertainty), a broader evidence base, reduction of generating evidence which is 
duplicative or inconsistent, improved engagement with patients, lower costs and management time, 
additionally being ethically superior by making better use of patient input. We will discuss each of 
these areas in turn, as well as where collaboration is most likely to be advantageous. 
Should a model be developed collaboratively by multiple companies, it would receive a much larger 
degree of scrutiny. Whilst this may take longer to achieve a final version, it also means mistakes are 
less likely to survive the process. With multiple companies also collaborating on model design, the 
resulting model is also more likely to generalise to the condition (rather than only apply to one 
treatment) – in that way the model is more likely to become accepted in the eyes of payers, and set 
the standard for that disease area, a benefit to the companies involved. 
Companies are also likely to be running trials in different stages of the disease – multiple myeloma 
being a good example with some companies investigating first line treatments, others second, and 
others third and beyond. By pooling resources there would be a broader evidence base, with 
companies able to ensure the inputs used from outside their own trial are robustly captured. The 
benefits here are twofold; firstly in more reliable estimates of inputs, and secondly in reduced cost 
of evidence generation (as this is shared) – this can be seen as a saving, or used for further evidence 
generation. 
By jointly developing a model, companies also have the potential to work with patient groups in a 
less transactional way. This can be used to get meaningful input – from the patient experience of the 
disease (and ensuring the model reflects this) to helping to populate health states (for example on 
working hours lost). Whilst this is possible for individual companies, it is less straightforward. Rare 
disease also only have a small pool of patients therefore a continuous stream of requests from 
different pharmaceutical companies may exhaust the goodwill of patients. Collecting data once (and 
comprehensively) in an effort to improve the modelling of the disease is preferable; such studies can 
then provide invaluable input to modellers and payers [6]. 
The lower cost of collaboration should also be addressed – whilst a more complex and adaptable 
model may cost more to construct, this is likely to be by a percentage, and not a factor. As the cost 
will be divided by at least 2 companies, in all cases this will result in a cost saving which increases as 
the number of collaborators increases. The true savings are much larger than they appear however – 
for example, systematic reviews will only have to be completed once with no extra cost to be 
delivered to multiple companies whilst the internal time taken to manage contractors is a substantial 
element of the cost of modelling and would be reduced. With a contractor responsible for delivery 
to multiple companies, this element is shifted to the modelling agency (and explicitly costed in), 
rather than absorbed internally. This internal time can mean savings on staff time, or give time for 
other activities. The cost is then also borne by companies who have the greatest incentive to collect 
accurate data, rather than being contingent on a third party as proposed by Afzali et al. [7]. 
An additional factor that should be considered are the ethics of collaboration, something seldom 
relevant in health economics. When patients enter in to clinical trials of novel treatments, they put 
their future health at risk to advance medical science. Whilst complete data sharing between 
companies who may be competitors is not expected, the hard earned data for patients on placebo 
treatment, for example, could be by multiple companies in their development programs – the 
sacrifice and risk taken by patients is therefore honoured and used for the benefit of the patient 
community. 
In practical terms the collaborative approach we propose at the company level is most likely to work 
in rare diseases, and in conditions where there have been no developments for many years. In rare 
conditions each company will be faced with the difficulty of understanding treatment pathways, and 
utilising scarce data to produce estimates – collaboration here is likely to help. Similarly in disease 
areas that have not had developments for some time (for example in melanoma prior to ipilumumab 
and vemurafenib [8]) similar problems apply as there is no best practice or established model, 
requiring a great deal of scoping and decision making. On the other hand collaboration will be more 
difficult where companies are on radically different timelines, or are likely to be competing for a 
finite pool of identical patients (for example the myriad of treatments for advanced or metastatic 
non-small cell lung cancer). 
Whilst there are many benefits to collaboration, there are a number of issues to consider prior to 
companies entering in to agreements; briefly we believe these to be the extent of data sharing, how 
the model should be maintained in the future, how costs should be shared (particularly if companies 
have different timelines, or slightly different needs), and how the project should be managed. The 
legal implications of collaborating will also need to be carefully worded so as not to infringe rules on 
collusion (as price will be an input in models). 
As a first step, Duchenne UK (a patient led charity) are currently proposing a collaboration between 
companies developing products in Duchenne muscular dystrophy (a rare muscle wasting disease 
affecting young boys). The disease pathway is complex, with current models not capturing important 
aspects of the condition and no data available for key inputs [9]. The goal of collaboration is to 
create a model which captures the entire disease pathway including joint research on the natural 
history of disease, quality of life data from all clinical trials, and populated with other information 
collected from patient groups (for example on carer burden and out of pocket costs).  
Ultimately whilst collaboration is not suitable for every area, we find the status quo wasteful. The 
current situation squanders time and money (which must be covered by increased prices, or lower 
returns), lowers quality (in turn increasing the chance of mistakes in resource allocation), increases 
uncertainty in modelling, and does not adequately respect the data generated from patients. When 
looking at upcoming projects, we urge companies to look beyond their own walls, and see if there is 
a way to do more with less - improving outcomes for all. 
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